ASPHALION experts Marta Morales and Enrique Gutierrez participated in the 30-month follow-up and review meeting of the Horizon project Tumor-LN-oC. The partners, with different specialities and background, gathered in Neuchatel to review the progress from the last 6 months. Asphalion, as regulatory affairs partner, presented the next steps of the regulatory strategy, including the attendance to an upcoming ITF meeting at the end of November.
The EU-funded Tumor-LN-oC project proposes the development and validation of a TRL 5 tumor-lymph node-on-chip platform composed of 3D tissue models and microfluidic chips, which will connect surgically removed human primary tumors and LN tissue from the same lung cancer patients. This will serve as a “biological twin” of the patient and will allow to study the interaction of primary tumors with LNs for individual patients.
For a complete overview of the Tumor-LN-oC project, we invite you to have a look at the website: https://tumor-ln-oc.eu/
For additional information and for all your EU-funded project, you can also contact us at: email@example.com